Gene expression profiling of lichenoid dermatitis immune‐related adverse event from immune checkpoint inhibitors reveals increased CD14⁺ and CD16⁺ monocytes driving an innate immune response

Abstract

LD-irAE exhibited activation of CD14/TLR innate immune response with increased CD14⁺ and CD16⁺ monocytes compared with BLK control. CD14/TLR signaling may drive the development of LD-irAE.